Routine CFO onboarding filing with zero ownership disclosed. No trading signal. Monitor future Form 4 filings for insider buying or selling activity.
SKYE drugs
SKYE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 29 $0.8940entry
- T+1 · 7mo ago −1.68%α −2.70% · $0.8790
- T+5 · 7mo ago −4.81%α −7.92% · $0.8510
- T+20 · 6mo ago −4.92%α −10.97% · $0.8500
- T+60 · 4mo ago −27.08%α −31.19% · $0.6519
Price Chart
How similar events traded
Executive Summary
John P. Sharp filed a Form 3 initial statement of beneficial ownership, reporting no securities owned, in connection with his appointment as Chief Financial Officer of Skye Bioscience, Inc. This is a routine administrative filing for a new officer with no financial data or trading activity disclosed.
Key Facts
- John P. Sharp appointed Chief Financial Officer of Skye Bioscience, Inc.
- Form 3 filed on 2026-04-28, reporting period 2026-03-31
- Reporting person owns 0 shares of common stock
- No derivative securities reported
Financial Impact
No financial impact, zero securities reported
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001628280-26-028062 |
| Document: 0001628280-26-028062-index-headers.html | 0001628280-26-028062 |
| Document: 0001628280-26-028062-index.html | 0001628280-26-028062 |
| Document: 0001628280-26-028062.txt | 0001628280-26-028062 |
Track record
16 reports on SKYE
5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +82.80% at T+60 after the Aug 14, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago DEFA14A Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
- Oct 26, 202621d ago PREM14A Bearish 7/10 Entry $1.45 Now $1.07 +26.55% settles Nov 24
- Oct 14, 20264w ago SC 13G Neutral 4/10 Entry $1.59 to $1.08 Now $1.07 −33.02% ▼ −32.08% −30.17% vs SPY
- Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $1.67 to $1.54 Now $1.07 −36.23% ▼ −7.78% −6.31% vs SPY
- Sep 24, 20267w ago SC 13D/A Bearish 6/10 Entry $1.67 to $1.54 Now $1.07 +36.23% ▲ +7.78% +6.31% vs SPY
- Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $1.78 to $1.53 Now $1.07 +40.17% ▲ +14.04% +13.14% vs SPY
- Aug 19, 202612w ago DEFA14A Neutral 4/10 Entry $0.2809 to $0.2206 Now $1.07 +279.14% ▼ −21.46% −21.34% vs SPY
- Aug 14, 202613w ago 8-K Mixed 7/10 Entry $0.5015 to $0.2487 Now $1.07 +112.36% ▼ −50.40% −48.41% vs SPY
- Aug 14, 202613w ago Press Release Bearish 7/10 Entry $0.5015 to $0.2487 Now $1.07 −112.36% ▲ +50.40% +48.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers